Recent studies have demonstrated that taxol, a naturally occurring antimitotic agent, was able to induce apoptotic cell death in a number of solid tumor cells, but it is unclear whether this finding has suggested a novel mechanism of action for taxol against tumors or just represents an end product of taxol's well-known effects on microtubules and mitotic arrest. Recent experiments in our laboratory demonstrated that taxol's cell-killing activity (but not mitotic arrest) could be selectively inhibited if tumor cells were pretreated with glucocorticoids, suggesting that taxol-induced apoptosis might occur via a signaling pathway independent of mitotic arrest. Since glucocorticOids (such as dexamethasone) are routinely used in the clinical application of taxol to prevent hypersensitivity reactions, this finding also raises a clinically relevant question as to whether pretreatment with glucocorticoids might actually interfere with taxol's antitumor efficacy. There are two interrelated research goals for this proposal: 1) to investigate the mechanism by which glucocorticoids inhibit taxol's action in solid tumor cells, and 2) to determine the molecular basis of taxol- induced apoptosis and its relationship with taxol's other well-known cellular effects on microtubules and cell cycle arrest. By utilizing the unique inhibitory feature of glucocorticoids on taxol's action, a step-by- step experimental approach is designed to accomplish these objectives: 1) Following the """"""""microtubule pathway"""""""", the potential influence of glucocorticoids on taxol's action in this well-characterized pathway will be analyzed; 2) Through pre-synchronization and other approaches, we will examine the possible correlation between taxol-induced apoptosis and cell cycle arrest, and clarify if taxol can exert its cell-killing activity via a separate pathway independent of mitotic arrest; 3) To characterize the cellular or molecular events occurring downstream of mitotic arrest and determine if glucocorticoids can specifically interfere with these events; 4) Through cloning and characterization of genes responsive to taxol, we will identify genes whose altered expression or modification are potentially involved in the mediation of taxol's action and/or glucocorticoid-mediated drug resistance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA071851-03
Application #
2769881
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Wolpert, Mary K
Project Start
1996-09-01
Project End
2001-08-31
Budget Start
1998-09-01
Budget End
2001-08-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Pathology
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Fan, Weimin; Sui, Meihua; Huang, Yi (2004) Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: mechanisms and its clinical impact. Curr Med Chem 11:403-11
Huang, Yi; Fan, Weimin (2002) IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol Pharmacol 61:105-13
Fu, L W; Deng, Z A; Pan, Q C et al. (2001) Screening and discovery of novel MDR modifiers from naturally occurring bisbenzylisoquinoline alkaloids. Anticancer Res 21:2273-80
Huang, Y; Johnson, K R; Norris, J S et al. (2000) Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60:4426-32
Zeng, S; Chen, Y Z; Fu, L et al. (2000) In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells. Clin Cancer Res 6:3766-73
Fan, W (1999) Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57:1215-21
Miller 3rd, M C; Johnson, K R; Willingham, M C et al. (1999) Apoptotic cell death induced by baccatin III, a precursor of paclitaxel, may occur without G(2)/M arrest. Cancer Chemother Pharmacol 44:444-52
Schandl, C A; Li, S; Re, G G et al. (1999) Mitotic chromosomal bcl-2. I. Stable expression throughout the cell cycle and association with isolated chromosomes. J Histochem Cytochem 47:139-49
Schandl, C A; Li, S; Re, G G et al. (1999) Mitotic chromosomal bcl-2. II. Localization to interphase nuclei. J Histochem Cytochem 47:151-8
Johnson, K R; Young, K K; Fan, W (1999) Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy. Clin Cancer Res 5:2559-65

Showing the most recent 10 out of 12 publications